Last reviewed · How we verify
Norovirus Bivalent Vaccine
At a glance
| Generic name | Norovirus Bivalent Vaccine |
|---|---|
| Sponsor | Takeda |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha) (PHASE3)
- A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants (PHASE1)
- A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old (PHASE1)
- Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants (PHASE1)
- Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults (PHASE2)
- Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha) (PHASE2)
- Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines (PHASE1)
- Recombinant, Bivalent, Norovirus Vaccine Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norovirus Bivalent Vaccine CI brief — competitive landscape report
- Norovirus Bivalent Vaccine updates RSS · CI watch RSS
- Takeda portfolio CI